Spots Global Cancer Trial Database for carmustine
Every month we try and update this database with for carmustine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | NCT01476839 | Recurrent Adult... | basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la... | 18 Years - 70 Years | City of Hope Medical Center | |
| Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma | NCT00002988 | Brain and Centr... | carmustine irinotecan hydr... | 18 Years - | Duke University | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Chemotherapy in Treating Patients With Recurrent Malignant Glioma | NCT00002986 | Brain and Centr... | carmustine topotecan hydro... | 18 Years - | Duke University | |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | NCT00005987 | Multiple Myelom... | carmustine cyclophosphamid... dexamethasone etoposide filgrastim mitoxantrone hy... recombinant int... sargramostim bone marrow abl... peripheral bloo... radiation thera... | - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients | NCT02670109 | Triple-Negative... Residual Tumor | Carmustine Cyclophosphamid... Carboplatin Autologous Hema... Busulfan | 18 Years - 60 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00007852 | Lymphoma | rituximab carmustine cytarabine etoposide melphalan autologous hema... | 19 Years - | University of Nebraska | |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03019640 | Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo... | Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab | 15 Years - 70 Years | M.D. Anderson Cancer Center | |
| Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme | NCT00919737 | Malignant Gliom... | NPC-08 | 18 Years - 64 Years | Nobelpharma | |
| Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT01220297 | Hematologic Dis... Acute-graft-ver... Leukemia Non-Hodgkin Lym... Hodgkin Lymphom... | Sirolimus Mycophenolate m... Carmustine Etoposide Cyclophosphamid... FTBI | 2 Years - 60 Years | Stanford University | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | NCT00020943 | Lymphoma | filgrastim rituximab carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... methotrexate prednisone vincristine sul... peripheral bloo... | 18 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| Combination Chemotherapy in Treating Patients With Lymphoma | NCT00002835 | Lymphoma | Bleomycin Sulfa... Filgrastim (G-C... Recombinant Int... Carmustine Cisplatin (CDDP... Cyclophosphamid... Cytarabine (ARA... Etoposide (VP-1... Idarubicin Ifosfamide Leucovorin Calc... Melphalan Methotrexate Methylprednisol... mitoxantrone hy... Vincristine Sul... Peripheral Bloo... Radiation Thera... | 15 Years - 59 Years | M.D. Anderson Cancer Center | |
| Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme | NCT00002545 | Brain and Centr... | carmustine low-LET photon ... | 18 Years - | Radiation Therapy Oncology Group | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia | NCT00002638 | Leukemia | filgrastim sargramostim carmustine cyclophosphamid... cytarabine etoposide peripheral bloo... radiation thera... | 1 Year - 19 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00003346 | Melanoma (Skin) | acetaminophen acetylcysteine carmustine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme | NCT00006386 | Brain and Centr... | carmustine radiation thera... stereotactic ra... | - | Radiation Therapy Oncology Group | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00005589 | Lymphoma | filgrastim rituximab carmustine cyclophosphamid... cytarabine etoposide melphalan bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | NCT05228249 | Recurrent Diffu... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Autologous Hema... Carmustine Cytarabine Etoposide Loncastuximab T... Melphalan | 18 Years - | Fred Hutchinson Cancer Center | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003397 | Lymphoma | filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo... | 18 Years - 75 Years | University of Maryland, Baltimore | |
| Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma | NCT00025636 | Lymphoma | filgrastim carmustine cisplatin cyclophosphamid... cytarabine dexamethasone etoposide melphalan methotrexate vincristine sul... bone marrow abl... peripheral bloo... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | NCT02329080 | Diffuse Large B... | Methotrexate Rituximab Cytarabine Thiotepa liposomial cyta... Etoposide Ifosfamide Carmustine whole brain rad... | 18 Years - 70 Years | International Extranodal Lymphoma Study Group (IELSG) | |
| Carmustine in Treating Patients With Recurrent Malignant Glioma | NCT00004028 | Brain and Centr... | carmustine conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion | NCT03570983 | Multiple Myelom... | Allopurinol Carmustine Etoposide Cytarabine Melphalan | 18 Years - 70 Years | Swedish Medical Center | |
| Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | NCT00002556 | Stage I Multipl... Stage II Multip... Stage III Multi... | vincristine sul... carmustine melphalan cyclophosphamid... prednisone recombinant int... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma | NCT00052923 | Lymphoma | filgrastim rituximab carmustine cyclophosphamid... etoposide peripheral bloo... radiation thera... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | NCT00716066 | Autoimmune Dise... Neurologic Auto... Autologous Tran... Multiple Sclero... MS Stem Cell Tr... Multiple Sclero... Stiff Person Sy... HCT for Neurolo... CIDP Transplant Myasthenia Grav... Autoimmune Nerv... Central Nervous... Cerebellar Dege... Chronic Inflamm... Lambert Eaton M... Myasthenia Grav... Neuromyelitis O... Opsoclonus Myoc... Rasmussen Subac... | Anti-Thymocyte ... Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Melphalan Peripheral Bloo... Prednisone Syngeneic Bone ... | - 71 Years | Fred Hutchinson Cancer Center | |
| O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors | NCT00003765 | Brain and Centr... | O6-benzylguanin... carmustine | - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | NCT00003815 | Lymphoma | bleomycin sulfa... carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide melphalan prednisolone vincristine sul... autologous bone... radiation thera... | 15 Years - 65 Years | National Cancer Institute (NCI) | |
| Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma | NCT00569985 | Lymphoma | lentivirus vect... carmustine cyclophosphamid... etoposide autologous hema... | 18 Years - 60 Years | City of Hope Medical Center | |
| S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | NCT00723658 | Lymphoma | rituximab bortezomib carmustine cisplatin cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide melphalan thalidomide autologous-auto... peripheral bloo... | 18 Years - | SWOG Cancer Research Network | |
| A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | NCT05540340 | Lymphoma Lymphoma, B-Cel... Lymphoma, T-Cel... Lymphoma, Hodgk... Lymphoma, Non-H... | Pharmacokinetic... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | NCT05540340 | Lymphoma Lymphoma, B-Cel... Lymphoma, T-Cel... Lymphoma, Hodgk... Lymphoma, Non-H... | Pharmacokinetic... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | NCT01008462 | B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac... | Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | NCT00723658 | Lymphoma | rituximab bortezomib carmustine cisplatin cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide melphalan thalidomide autologous-auto... peripheral bloo... | 18 Years - | SWOG Cancer Research Network | |
| O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma | NCT00005961 | Melanoma (Skin) | O6-benzylguanin... carmustine | 18 Years - | National Cancer Institute (NCI) | |
| S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | NCT00002772 | Breast Cancer | filgrastim carboplatin carmustine cisplatin cyclophosphamid... doxorubicin hyd... paclitaxel tamoxifen citra... thiotepa autologous bone... peripheral bloo... radiation thera... | 18 Years - | SWOG Cancer Research Network | |
| Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma | NCT00003467 | Brain and Centr... | carmustine polifeprosan 20... surgical proced... | 18 Years - | Duke University | |
| O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma | NCT00004072 | Multiple Myelom... | O6-benzylguanin... carmustine | - | Case Comprehensive Cancer Center | |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | NCT00992446 | Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg... | Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma | NCT00002676 | Lymphoma | carmustine cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... methotrexate vincristine sul... low-LET cobalt-... low-LET photon ... | 18 Years - 70 Years | Alliance for Clinical Trials in Oncology | |
| Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma | NCT00003467 | Brain and Centr... | carmustine polifeprosan 20... surgical proced... | 18 Years - | Duke University | |
| Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT00908180 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cyclosporine cytarabine etoposide melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | NCT02342782 | Mature T-Cell a... Recurrent Matur... Refractory Matu... Recurrent Cutan... Refractory Cuta... | Yttrium Y 90 Ba... Carmustine Etoposide Cytarabine Melphalan Autologous Hema... Laboratory Biom... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | NCT00472056 | Lymphoma | Carmustine Etoposide Cytarabine Melphalan Rituximab | - 80 Years | M.D. Anderson Cancer Center | |
| Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme | NCT00027612 | Brain and Centr... | carmustine irinotecan hydr... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | NCT03072771 | Diffuse Large B... | Blinatumomab Autologous stem... Carmustine Etoposide Cytarabine Melphalan Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma | NCT00005637 | Brain and Centr... | carmustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma | NCT00003578 | Lymphoma | CHOP regimen carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide melphalan prednisone vincristine sul... autologous bone... peripheral bloo... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | NCT05521984 | Pediatric Brain... | Dapagliflozin Carmustine | 6 Years - 21 Years | Washington University School of Medicine | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00005589 | Lymphoma | filgrastim rituximab carmustine cyclophosphamid... cytarabine etoposide melphalan bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02443077 | Recurrent Diffu... Refractory Diff... | Autologous Bone... Autologous Hema... Carmustine Cyclophosphamid... Cytarabine Etoposide Ibrutinib Laboratory Biom... Melphalan Pharmacogenomic... Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | NCT03579927 | CD19 Positive Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Refractory B-Ce... Refractory Diff... Refractory Foll... | Autologous Hema... Carmustine Cytarabine Etoposide Filgrastim Melphalan Rituximab Umbilical Cord ... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | NCT00020943 | Lymphoma | filgrastim rituximab carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... methotrexate prednisone vincristine sul... peripheral bloo... | 18 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma | NCT00003467 | Brain and Centr... | carmustine polifeprosan 20... surgical proced... | 18 Years - | Duke University | |
| Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation | NCT01653418 | Multiple Myelom... | Bortezomib Carmustine Etoposide Cytarabine Melphalan Stem cell infus... | 18 Years - | Washington University School of Medicine | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | NCT00006747 | Graft Versus Ho... Lymphoma | carmustine melphalan etoposide cytarabine tacrolimus methotrexate sargramostim transplant | - 59 Years | Alliance for Clinical Trials in Oncology | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | NCT01656980 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine tumor resection... | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00086879 | Brain and Centr... | carmustine erlotinib hydro... temozolomide | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant | NCT00439556 | CD20 Positive Hematopoietic a... Lymphocytic Neo... Lymphoma | Allogeneic Hema... Anti-Thymocyte ... Bortezomib Carmustine Cytarabine Etoposide Filgrastim Melphalan Methotrexate Rituximab Tacrolimus | - 70 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | NCT01656980 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine tumor resection... | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | NCT02059239 | Hodgkin's Lymph... Non-Hodgkin's L... | Bendamustine Carmustine Etoposide Melphalan Cytarabine Alemtuzumab Autologous Stem... Allogeneic Stem... Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | NCT02329080 | Diffuse Large B... | Methotrexate Rituximab Cytarabine Thiotepa liposomial cyta... Etoposide Ifosfamide Carmustine whole brain rad... | 18 Years - 70 Years | International Extranodal Lymphoma Study Group (IELSG) | |
| Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain | NCT00003348 | Brain and Centr... | O6-benzylguanin... carmustine | 18 Years - | Duke University | |
| Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00005998 | Lymphoma | carmustine cyclophosphamid... cytarabine dexamethasone etoposide filgrastim mitoxantrone hy... retrovirus vect... in vitro-treate... peripheral bloo... radiation thera... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | NCT00720447 | Lymphoma | alemtuzumab donor lymphocyt... carmustine cytarabine etoposide melphalan allogeneic bone... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | NCT00003399 | Multiple Myelom... | carmustine cisplatin cyclophosphamid... dexamethasone etoposide melphalan paclitaxel in vitro-treate... | 18 Years - 70 Years | University of Maryland, Baltimore |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
